On Monday, Bristol-Myers Squibb Co (NYSE: BMY) was 10.49% up from the session before settling in for the closing price of $54.14. A 52-week range for BMY has been $39.35 – $56.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 16.92%. When this article was written, the company’s average yearly earnings per share was at -88.39%. With a float of $2.03 billion, this company’s outstanding shares have now reached $2.03 billion.
The extent of productivity of a business whose workforce counts for 34100 workers is very important to gauge. In terms of profitability, gross margin is 70.41%, operating margin of 26.81%, and the pretax margin is -14.5%.
Bristol-Myers Squibb Co (BMY) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Bristol-Myers Squibb Co stocks. The insider ownership of Bristol-Myers Squibb Co is 0.08%, while institutional ownership is 77.26%. The most recent insider transaction that took place on Nov 04 ’24, was worth 38,930. In this transaction SVP and Controller of this company sold 700 shares at a rate of $55.62, taking the stock ownership to the 11,760 shares. Before that another transaction happened on Nov 01 ’24, when Company’s EVP,Chief Med.Offr.,Drug Dev. bought 1,830 for $54.67, making the entire transaction worth $100,055. This insider now owns 62,109 shares in total.
Bristol-Myers Squibb Co (BMY) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -88.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.66% during the next five years compared to 5.14% growth over the previous five years of trading.
Bristol-Myers Squibb Co (NYSE: BMY) Trading Performance Indicators
You can see what Bristol-Myers Squibb Co (BMY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.53. Likewise, its price to free cash flow for the trailing twelve months is 8.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.60, a number that is poised to hit 1.47 in the next quarter and is forecasted to reach 7.06 in one year’s time.
Technical Analysis of Bristol-Myers Squibb Co (BMY)
The latest stats from [Bristol-Myers Squibb Co, BMY] show that its last 5-days average volume of 14.04 million was inferior to 14.46 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 62.23%. Additionally, its Average True Range was 1.68.
During the past 100 days, Bristol-Myers Squibb Co’s (BMY) raw stochastic average was set at 94.20%, which indicates a significant increase from 86.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.39% in the past 14 days, which was higher than the 33.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $52.07, while its 200-day Moving Average is $48.13. Now, the first resistance to watch is $60.76. This is followed by the second major resistance level at $61.69. The third major resistance level sits at $62.31. If the price goes on to break the first support level at $59.21, it is likely to go to the next support level at $58.59. The third support level lies at $57.66 if the price breaches the second support level.
Bristol-Myers Squibb Co (NYSE: BMY) Key Stats
There are 2,028,177K outstanding shares of the company, which has a market capitalization of 120.06 billion. As of now, sales total 45,006 M while income totals 8,025 M. Its latest quarter income was 11,892 M while its last quarter net income were 1,211 M.
